Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
Novavax incurred a third-quarter 2024 loss of 76 cents per share, narrower than the Zacks Consensus Estimate of a loss of 87 cents. In the year-ago quarter, the company reported a loss of $1.26 per ...
Syndax Pharmaceuticals: Promising Phase 2 Results Justify Buy Rating Amid Market Undervaluation
Mizuho Securities analyst Salim Syed has maintained their bullish stance on SNDX stock, giving a Buy rating yesterday. Salim Syed has given ...
Kura Oncology Positioned for Growth with Promising Menin Inhibitor Ziftomenib Amidst Competitor Challenges
Leerink Partners analyst Jonathan Chang has maintained their bullish stance on KURA stock, giving a Buy rating on November 12. Jonathan ...
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their ...
NDRI CEO Bill Leinweber Appointed to Pennsylvania Organ Donation Advisory Committee
PHILADELPHIA--The National Disease Research Interchange (NDRI) is proud to announce that Pennsylvania Governor Josh Shapiro ...
NDTV12h
World News
More than 40,000 Gen Z and millennial Bumble users worldwide, including over 2,000 singles in India, participated in the survey.